Results 1 to 10 of about 14,613 (227)

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial [PDF]

EBioMedicine, 2015
Background: Abnormalities in membrane excitability and Na+ channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+ channel blocker and membrane ...
Steve Vucic, Susanna B Park
exaly   +4 more sources

Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action

Cells, 2021
Cardiac ryanodine receptor (RyR2) mutations are implicated in the potentially fatal catecholaminergic polymorphic ventricular tachycardia (CPVT) and in atrial fibrillation.
Samantha C. Salvage, Esther M. Gallant, James A. Fraser, Christopher L.-H. Huang, Angela F. Dulhunty   +4 more
doaj   +2 more sources

The Frontal QRS-T Angle Remains Unchanged in Patients Without Structural Heart Disease Receiving Flecainide Therapy [PDF]

Journal of Cardiovascular Development and Disease
Introduction: Prolongation of the QT interval and QRS duration, which are markers of ventricular repolarization and depolarization, has been reported in patients receiving flecainide therapy.
Mehmet Kucukosmanoglu, Mustafa Lutfullah Ardıc, Fadime Koca, Hilmi Erdem Sumbul, Mevlut Koc   +4 more
doaj   +2 more sources

Comparative effectiveness and safety of vernakalant, flecainide, and amiodarone for atrial fibrillation cardioversion: a propensity score–matched analysis [PDF]

BMC Emergency Medicine
Background Vernakalant is approved in Europe, Canada, and several Asian countries for the pharmacological cardioversion of recent-onset atrial fibrillation (AF), but remains unauthorized in the United States due to FDA safety concerns.
Giuseppe Dominijanni, Antonio F. Caballero-Bermejo, Álvaro Pineda-Torcuato, Ana Sainz-Herrero, Rosa Capilla-Pueyo, Belén Ruiz-Antorán   +5 more
doaj   +2 more sources

Flecainide in Structural Heart Disease: Reconsidering Its Role in Contemporary Arrhythmia Management [PDF]

Life
Background: Flecainide has remained largely excluded from use in structural heart disease for more than three decades, mainly because of the Cardiac Arrhythmia Suppression Trial, which showed excess mortality in post-myocardial infarction patients ...
Paschalis Karakasis, Konstantinos Grigoriou, Panagiotis Theofilis, Panagiotis Iliakis, Panayotis K. Vlachakis, Nikolaos Ktenopoulos, Anastasios Apostolos, Dimitrios Patoulias, Antonios P. Antoniadis, Nikolaos Fragakis   +9 more
doaj   +2 more sources

Left atrial strain compared to volume in long-term flecainide treated patients with atrial fibrillation – a retrospective cohort study [PDF]

BMC Cardiovascular Disorders
Background Left atrial volume index (LAVI) is associated with recurrent atrial fibrillation (AF) during flecainide treatment. Nevertheless, AF patients with normal LAVI experience rhythm control failure.
Alexander Siotis, Pyotr G. Platonov, Bjarne Madsen Hardig   +2 more
doaj   +2 more sources

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

Frontiers in Pharmacology, 2023
Background and purpose: While flecainide is now an accepted treatment for arrhythmias associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), its mechanism of action remains controversial.
Emma J. Steer, Zhaokang Yang, Moza M. Al-Owais, Hannah M. Kirton, Edward White, Derek S. Steele   +5 more
doaj   +1 more source

Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report

International Breastfeeding Journal, 2023
Background Mothers requiring the antiarrhythmic agent flecainide are often advised not to breastfeed, because of the lack of data concercing neonatal effects and flecainide plasma concentrations following maternal exposure as well as via lactation.
Johanna A. van der Zande, Jérôme M.J. Cornette, Jolien W. Roos-Hesselink, Robert B. Flint   +3 more
doaj   +1 more source

Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia

Frontiers in Pediatrics, 2023
Flecainide is a class IC antiarrhythmic utilized in prophylaxis of refractory paroxysmal supraventricular tachycardias in pediatric populations. Despite being a highly effective agent, its narrow therapeutic index increases the risk of toxicity and ...
Ronald Palmen, Ronald Palmen, Ronald Palmen, Tracy Sandritter, Tracy Sandritter, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Lindsey Malloy-Walton, Christopher Follansbee, Christopher Follansbee, Christopher Follansbee, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner, Jonathan B. Wagner   +15 more
doaj   +1 more source

Flecainide for conversion and maintenance of sinus rhythm after mitral valve replacement in rheumatic atrial fibrillationWhat is Already Known?What this Study Adds

Indian Heart Journal, 2023
Background: Despite successful mitral valve replacement (MVR), many patients remain in AF. Flecainide can be useful in these patients but has not been used because of underlying structural heart disease.
Umesh Tripathi, Aditya Kapoor, Surendra Kumar Agarwal, Prabhat Tewari, Shantanu Pande, Bipin Chandra, Ankit Sahu, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari   +10 more
doaj   +1 more source